Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
CagriSema (the combination) was submitted for FDA approval in December 2025, but cagrilintide on its own is earlier in the process
I could hardly walk or move my gingers because of all the inflammation I had
Patients should speak to their GP if their BMI is 30 or above (or 27.5 or above in certain ethnic groups with higher metabolic risk), particularly if they have related conditions such as type 2 diabetes, hypertension, or sleep apnoea
US$ 29.43
US$ 27.62
US$ 27.39
